Amlodipine And Olmesartan Medoxomil
Product Images NDC 45865-947

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Amlodipine And Olmesartan Medoxomil (NDC 45865-947). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (947)

Label for Amlodipine and Olmesartan Medoxomil tablets, 10/40 mg strength, marketed as a generic for Azor by Glenmark Pharmaceuticals, LTD. The label indicates a quantity of 30 tablets and includes warnings about dizziness and precautions for pregnant women. The labeler is Medsource Pharmaceuticals with NDC 45865-0947.*

FDA Label Image

Amlodipine.jpg (Amlodipine)

Chemical structure of the active ingredients in Amlodipine and Olmesartan Medoxomil, showing the molecular components and arrangement relevant to these compounds used in the medication.*

FDA Label Image

Figure1.jpg (Figure1)

A line graph illustrating the percentage of systolic blood pressure (SBP) below 140 mmHg relative to baseline SBP (mmHg). It compares the effects of placebo, Amlodipine 10 mg, Olmesartan Medoxomil 40 mg, and Amlodipine and Olmesartan Medoxomil 10/40 mg combination tablets. The horizontal axis represents baseline SBP values from 140 to 180 mmHg, and the vertical axis shows the percentage achieving SBP < 140 mmHg, ranging from 0 to 100%.*

FDA Label Image

Figure2.jpg (Figure2)

A line graph comparing the percentage of subjects with diastolic blood pressure (DBP) below 90 mmHg at various baseline DBP levels (95 to 110 mmHg) for four groups: Placebo, OM40 mg, AML10 mg, and Amlodipine and olmesartan medoxomil tablets 10/40 mg. The graph illustrates the relative effectiveness of these treatments in lowering DBP.*

FDA Label Image

Figure3.jpg (Figure3)

A line chart comparing the percentages of subjects with systolic blood pressure (SBP) less than 130 mm Hg against baseline SBP values (140 to 180 mm Hg) for placebo, AML 10 mg, OM 40 mg, and Amlodipine and Olmesartan Medoxomil 10/40 mg tablets.*

FDA Label Image

Figure4.jpg (Figure4)

A line graph comparing the percentage of diastolic blood pressure (DBP) measurements below 80 mmHg against baseline DBP values (95 to 110 mmHg) for different treatments: placebo, Amlodipine 10 mg, Olmesartan Medoxomil 40 mg, and the combination of Amlodipine and Olmesartan Medoxomil 10/40 mg tablets.*

FDA Label Image

Olmesartanmedoxomil.jpg (Olmesartanmedoxomil)

Chemical structure of the active ingredients in Amlodipine and Olmesartan Medoxomil, showing detailed molecular arrangement including various rings and functional groups characteristic of these compounds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.